OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
065510$7530.0058

Huvitz Co Ltd

Advanced Medical Equipment & TechnologyVerified

Huvitz Co Ltd operates with a debt-to-equity ratio of 0.73 and a current ratio of 1.07, indicating moderate liquidity risk. The company's price-to-book ratio is 0.75, and its price-to-tangible-book ratio is also 0.75, suggesting that the market values the company's tangible assets at a discount to its equity value. The company's negative net income of -4,973,820,460 KRW and negative operating income of -4,729,657,540 KRW indicate a lack of profitability. The company's return on equity (ROE) is -4.71%, and its return on assets (ROA) is -2.21%, both significantly below the industry median for Advanced Medical Equipment & Technology. The gross profit margin is 45.53% (53,736,403,210 KRW / 118,043,310,690 KRW), which is in line with the industry median, but the operating margin is -4.01% (-4,729,657,540 KRW / 118,043,310,690 KRW), indicating operational inefficiencies. Huvitz's revenue is primarily concentrated in its domestic market, with no disclosed international revenue segments. The company's revenue concentration in a single geographic region increases its exposure to local economic and regulatory risks. The company's revenue for the latest period is 118,043,310,690 KRW, and there are no disclosed growth projections for the current or next fiscal year. The company's free cash flow is negative at -7,265,051,230 KRW, and its capital expenditure is -7,618,972,960 KRW, indicating that the company is investing in its operations but is not generating sufficient cash to cover these investments. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face challenges in meeting its short-term obligations. The company's valuation adjustments and dilution potential are not disclosed in the provided data. Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's latest actual EPS is -461.00 KRW, and its latest actual revenue is 118,093,000,000 KRW, indicating a lack of earnings growth.

30-day price · 065510-570.00 (-7.4%)
Low$7110.00High$8180.00Close$7180.00As of22 May, 00:00 UTC
Profile
CompanyHuvitz Co Ltd
Ticker065510.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Huvitz Co Ltd is a Korea-based company engaged in the manufacture and sale of ophthalmic medical devices, including automatic optometry machines, automatic lens meters, lens processing machines, reflectors, and ophthalmic diagnostic equipment.

Classification. Huvitz is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

Huvitz Co Ltd operates with a debt-to-equity ratio of 0.73 and a current ratio of 1.07, indicating moderate liquidity risk. The company's price-to-book ratio is 0.75, and its price-to-tangible-book ratio is also 0.75, suggesting that the market values the company's tangible assets at a discount to its equity value. The company's negative net income of -4,973,820,460 KRW and negative operating income of -4,729,657,540 KRW indicate a lack of profitability. The company's return on equity (ROE) is -4.71%, and its return on assets (ROA) is -2.21%, both significantly below the industry median for Advanced Medical Equipment & Technology. The gross profit margin is 45.53% (53,736,403,210 KRW / 118,043,310,690 KRW), which is in line with the industry median, but the operating margin is -4.01% (-4,729,657,540 KRW / 118,043,310,690 KRW), indicating operational inefficiencies. Huvitz's revenue is primarily concentrated in its domestic market, with no disclosed international revenue segments. The company's revenue concentration in a single geographic region increases its exposure to local economic and regulatory risks. The company's revenue for the latest period is 118,043,310,690 KRW, and there are no disclosed growth projections for the current or next fiscal year. The company's free cash flow is negative at -7,265,051,230 KRW, and its capital expenditure is -7,618,972,960 KRW, indicating that the company is investing in its operations but is not generating sufficient cash to cover these investments. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face challenges in meeting its short-term obligations. The company's valuation adjustments and dilution potential are not disclosed in the provided data. Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's latest actual EPS is -461.00 KRW, and its latest actual revenue is 118,093,000,000 KRW, indicating a lack of earnings growth.
Key takeaways
  • Huvitz Co Ltd is a manufacturer of ophthalmic medical devices with a focus on domestic sales.
  • The company is currently unprofitable, with negative operating and net income.
  • The company's liquidity position is moderate, with a current ratio of 1.07 and a debt-to-equity ratio of 0.73.
  • The company's ROE and ROA are significantly below the industry median, indicating poor returns on equity and assets.
  • The company's revenue is concentrated in a single geographic region, increasing its exposure to local economic and regulatory risks.
  • The company's free cash flow is negative, and its capital expenditure is high, indicating that the company is investing in its operations but is not generating sufficient cash to cover these investments.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$118.04B
Gross profit$53.74B
Operating income-$4.73B
Net income-$4.97B
R&D
SG&A
D&A
SBC
Operating cash flow$12.66B
CapEx-$7.62B
Free cash flow-$7.27B
Total assets$224.76B
Total liabilities$119.24B
Total equity$105.52B
Cash & equivalents$250.00
Long-term debt$77.17B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$7530.00
Market cap$79.45B
Enterprise value$156.62B
P/E
Reported non-GAAP P/E
EV/Revenue1.3
EV/Op income
EV/OCF12.4
P/B0.8
P/Tangible book0.8
Tangible book$105.52B
Net cash-$77.17B
Current ratio1.1
Debt/Equity0.7
ROA-2.2%
ROE-4.7%
Cash conversion-2.5%
CapEx/Revenue-6.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric065510Activity
Op margin-4.0%-24.0% medp25 -212.9% · p75 6.1%above median
Net margin-4.2%-20.7% medp25 -188.5% · p75 4.8%above median
Gross margin45.5%49.8% medp25 36.6% · p75 67.4%below median
CapEx / revenue-6.5%-4.7% medp25 -11.2% · p75 -1.8%below median
Debt / equity73.0%3.6% medp25 0.0% · p75 22.2%top quartile
Observations
IR observations
Last actual EPS-461.00 KRW
Last actual revenue118,093,000,000 KRW
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 04:40 UTC#2127e129
Market quoteclose KRW 7530.00 · shares 0.01B diluted
no public URL
2026-05-10 04:40 UTC#bc44a6c5
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 04:42 UTCJob: a3d18a70